Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine

Neurology

Volumn 49, Issue 5, 1997, Pages 1219-1225

  Solomon, G D ^a   Cady, R K ^b   Klapper, J A ^c   Earl, N L ^d,e   Saper, J R ^f   Ramadan, Nabih M ^g,h  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HEADACHE CARE CENTER   (United States)

^c Colorado Neurol and Headache Center ^*  (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Michigan Hd Pain Neurologic Inst   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLMITRIPTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VERTIGO;

EID: 0030695880     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.5.1219     Document Type: Article

References (14)

1. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-660.
2. Lance JW. Current concepts of migraine pathogenesis. Neurology 1993;43(6 suppl 3):S11-S15.
3. Moskowitz MA. The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology 1991;41: 182-186.
4. Peroutka SJ. Sumatriptan in acute migraine: pharmacology and review of world experience. Headache 1990;30(suppl 2): 554-560.
5. 1D receptor: discovery of compounds with potential anti-migraine properties. J Med Chem 1995;38: 3566-3580.
6. Martin GR, Dixon RM. Preclinical and clinical pharmacology of the novel antimigraine compound, 311C90 [abstract]. Headache 1995;35:291.
7. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996; 46:522-526.
8. Goadsby PJ, Edvinsson L. Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994;34:394-399.
9. 1B/1D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996;67(2-3):355-359.
10. Rapoport AM, Cady RK, Matthew NT, et al. Optimizing the oral dose of 311C90 in the acute treatment of migraine [abstract]. Cephalalgia 1995;15(suppl 14):221.
11. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
12. 1D receptor agonists for the treatment of migraine attacks. In: Olesen J, Tfelt-Hansen P, eds. Headache treatment: trial methodology and new drugs. Philadelphia: Lippincott-Raven, 1997:253-256.
13. Tfelt-Hansen P. Methodology of treatment trials for acute migraine attacks. In: Olesen J, Tfelt-Hansen P, eds. Headache treatment: trial methodology and new drugs. Philadelphia: Lippincott-Raven, 1997:111-117.
14. Bousser MG, D'Allens H, Richard A, Early-Morning Migraine Sumatriptan Study Group. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med 1993;234:211-216.